A practical reference on incretin: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-14. Anything still debated is marked as such rather than presented as settled.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
=== 2020: US Open final === Zverev began his 2020 season at the inaugural ATP Cup. Germany was in Group F alongside Australia, Greece, and Canada. Against Australia, he lost to Alex de Minaur in three sets. Australia won the tie over Germany 3–0. Against Greece, he was defeated by Stefanos Tsitsipas. Germany won the tie over Greece 2–1. Against Canada, he was beaten by Denis Shapovalov. Canada won the tie over Germany 2–1. Germany ended third in Group F. Seeded seventh at the Australian Open, he first defeated Marco Cecchinato in the first round in straight sets. After the match, he pledged to donate all his prize money from the tournament to relief efforts for the ongoing bushfires if he won the title, a total of A$4.12 million. He then defeated Egor Gerasimov, Fernando Verdasco, and 17th seed Andrey Rublev to reach the quarterfinals without dropping a set. He defeated 15th seed and 2014 champion, Stan Wawrinka, in the quarterfinals in four sets to reach his first major singles semifinal. He fell in his semifinal match to fifth seed, Dominic Thiem, in four sets. During the week of 24 February, Zverev played at the Mexican Open. Seeded second, he was upset in his second-round match by qualifier Tommy Paul. Starting from 12 March through early August, the ATP suspended tournament play due to the COVID-19 pandemic. At the US Open, Zverev was seeded fifth. He defeated Kevin Anderson in four sets, then beat 19-year old Brandon Nakashima in four sets. In the third round, he beat Adrian Mannarino in four sets before beating Alejandro Davidovich Fokina in straight sets.
In centuries past, various kinds of chorea were at times called by names such as Saint Vitus' dance, with little or no understanding of their cause or type in each case. The first definite mention of HD was in a letter by Charles Oscar Waters (1816–1892), published in the first edition of Robley Dunglison's Practice of Medicine in 1842. Waters described "a form of chorea, vulgarly called magrums", including accurate descriptions of the chorea, its progression, and the strong heredity of the disease. In 1846 Charles Rollin Gorman (1817–1879) observed how higher prevalence seemed to occur in localized regions. Independently of Gorman and Waters, both students of Dunglison at Jefferson Medical College in Philadelphia, Johan Christian Lund (1830–1906) also produced an early description in 1860. He specifically noted that in Setesdalen, a secluded mountain valley in Norway, the high prevalence of dementia was associated with a pattern of jerking movement disorders that ran in families. The first thorough description of the disease was by George Huntington in 1872. Examining the combined medical history of several generations of a family exhibiting similar symptoms, he realized their conditions must be linked; he presented his detailed and accurate definition of the disease as his first paper. Huntington described the exact pattern of inheritance of autosomal dominant disease years before the rediscovery by scientists of Mendelian inheritance.
=== 2012–2018: Change in pace === He starred alongside former co-star Steve Carell in the Don Scardino-directed comedy film The Incredible Burt Wonderstone (2013). Carrey played Steve Gray, a dangerous street magician who overshadows the formerly successful magician Burt Wonderstone (played by Carell). The film was released in March 2013 to mixed reviews and underperformed significantly at the box office, grossing just over $27 million on a $30 million budget. Around the same time, he appeared in Kick-Ass 2 (also 2013) as Colonel Stars and Stripes. He retracted support for the film two months prior to its release. He issued a statement via his Twitter account that, in light of the Sandy Hook Elementary School shooting, "Now in all good conscience I cannot support that level of violence." Peter Farrelly said in April 2012 that Carrey and Jeff Daniels would return for a Dumb and Dumber sequel, Dumb and Dumber To, with the Farrelly brothers writing and directing and a planned September 2012 production start. In June, however, Carrey's representative said Carrey had left the project because the comedian felt New Line and Warner Bros. were unenthusiastic toward it. However, on October 1, 2012, Yahoo!'s The Yo Show carried the news item that the script was complete and that the original actors, Carrey and Daniels, would be reprising their roles. The plot involved one of the characters having sired a child and needing to find them to obtain a kidney. Dumb and Dumber To was released in November 2014.
Sources: en.wikipedia.org
The liver is the second largest organ (after the skin) and is an accessory digestive gland which plays a role in the body's metabolism. The liver has many functions some of which are important to digestion. The liver can detoxify various metabolites; synthesise proteins and produce biochemicals needed for digestion. It regulates the storage of glycogen which it can form from glucose (glycogenesis). The liver can also synthesise glucose from certain amino acids. Its digestive functions are largely involved with the breaking down of carbohydrates. It also maintains protein metabolism in its synthesis and degradation. In lipid metabolism it synthesises cholesterol. Fats are also produced in the process of lipogenesis. The liver synthesises the bulk of lipoproteins. The liver is located in the upper right quadrant of the abdomen and below the diaphragm to which it is attached at one part, the bare area of the liver. This is to the right of the stomach and it overlies the gall bladder. The liver synthesises bile acids and lecithin to promote the digestion of fat.
In Canada there had been no requirement to be circumspect when addressing the egalitarian New Zealander Rutherford, but many people in Germany found his manner off-putting, and characterised him as an "Anglicised Berliner". Hahn completed his habilitation in early 1907, and became a Privatdozent. A thesis was not required; the Chemical Institute accepted one of his publications on radioactivity instead. Most of the organic chemists at the Chemical Institute did not regard Hahn's work as real chemistry. Fischer objected to Hahn's contention in his habilitation colloquium that many radioactive substances existed in such tiny amounts that they could only be detected by their radioactivity, venturing that he had always been able to detect substances with his keen sense of smell, but soon gave in. One department head remarked: "it is incredible what one gets to be a Privatdozent these days!"
== Efforts to characterize all human cell types == Several efforts have been made to make a list or a map of all human cells. One of the largest and most recent is the HuBMAP (Human BioMolecular Atlas Program). The HuBMAP project has organized 1551 different samples in 17 collections, each dedicated to a different system. However, this project still only mapped about 31 of the human body's 70 organs. Their datasets and visualisations place great emphasis on biomarkers and location in the body, but less on cell development and how cells can change over time. Usually specific surface proteins are used to identify cells, and based on this they are put into different categories. Another major effort to make an overview of these proteins that allows us to observe cell types is the Human Protein Atlas. A similar project, the Human Brain Project has also attempted to map the human brain, although much of the publicly accessible model does not have cellular resolution.
== Etymology == The proposed name for the toxin is U7-ctenitoxin-Pn1a. Here, 'ctenitoxin' refers to toxins found in the venom of spiders from the Ctenidae family. 'Pn' is an acronym for Phoneutria nigriventer, referring to the genus and species of the animal it was isolated from. A commonly used alternative name for U7-CNTX-Pn1a is PnTx3-5, which is an acronym for Phoneutria nigriventer Toxin 3–5. Here, 3 refers to it being part of the third toxic protein fraction that was isolated from the venom using a technique involving a combination of gel filtration and reverse phase fast protein liquid chromatography. Similarly, 5 refers to it being the fifth peptide that was separated from this fraction through reverse phase and ion-exchange high-performance liquid chromatography.
Sources: en.wikipedia.org
, the Darcy friction factor (also called flow coefficient λ). For laminar flow in a circular pipe of diameter Dc, the friction factor is inversely proportional to the Reynolds number alone (fD = 64/Re) which itself can be expressed in terms of easily measured or published physical quantities (see section below). Making this substitution the Darcy–Weisbach equation is rewritten as
Following three constitutional conferences, the British North America Act, 1867 officially proclaimed Canadian Confederation on July 1, 1867, initially with four provinces: Ontario, Quebec, Nova Scotia, and New Brunswick. Canada assumed control of Rupert's Land and the North-Western Territory to form the Northwest Territories, where the Métis' grievances ignited the Red River Rebellion and the creation of the province of Manitoba in July 1870. British Columbia and Vancouver Island (which had been united in 1866) joined the confederation in 1871 on the promise of a transcontinental railway extending to Victoria in the province within 10 years, while Prince Edward Island joined in 1873. In 1898, during the Klondike Gold Rush in the Northwest Territories, Parliament created the Yukon Territory. Alberta and Saskatchewan became provinces in 1905. Between 1871 and 1896, almost one quarter of the Canadian population emigrated south to the US. To settle the West and attract European immigrants, Canada sponsored the construction of three transcontinental railways, enacted the Dominion Lands Act and founded the North-West Mounted Police to maintain regional authority. This period of westward expansion and nation building resulted in the displacement of many Indigenous peoples of the Canadian Prairies to "Indian reserves", clearing the way for ethnic European block settlements. This caused the collapse of the Plains Bison in western Canada and the introduction of European cattle farms and wheat fields dominating the land.
The most common unsupervised use of antihistamines in terms of volume and percentage of the total is perhaps in parallel to the medicinal use of some antihistamines to extend and intensify the effects of opioids and depressants. The most commonly used are hydroxyzine, mainly to extend a supply of other drugs, as in medical use, and the above-mentioned ethanolamine and alkylamine-class first-generation antihistamines, which are – once again as in the 1950s – the subject of medical research into their anti-depressant properties. For all of the above reasons, the use of medicinal scopolamine for recreational uses is also observed.
Using this technique the resolution of deuterium exchange is determined by the size of the peptides produced during digestion. Pepsin, an acid protease, is commonly used for proteolysis, as the quench pH must be maintained during the proteolytic reaction. To minimize the back-exchange, proteolysis and subsequent mass spectrometry analysis must be done as quickly as possible. HPLC separation of the peptic digest is often carried out at low temperature just prior to electrospray mass spectrometry to minimize back-exchange. More recently, UPLC has been used due to its superior separation capabilities. It was proposed in 1999 that it might be possible to achieve single-residue resolution by using collision-induced dissociation (CID) fragmentation of deuterated peptides in conjunction with tandem mass spectrometry. It was soon discovered that CID causes "scrambling" of the deuterium position within the peptides. However, fragmentation produced by MALDI in-source decay (ISD), electron capture dissociation (ECD), and electron transfer dissociation (ETD) proceed with little or no scrambling under the correct experimental conditions. Scrambling of the isotopic labeling is caused by collisional heating prior to dissociation of the ion and while CID do cause scrambling, collisional heating can also occur during ionization and ion transport.
The term fish processing refers to the processes associated with fish and fish products between the time fish are caught or harvested, and the time the final product is delivered to the customer. Although the term refers specifically to fish, in practice it is extended to cover any aquatic organisms harvested for commercial purposes, whether caught in wild fisheries or harvested from aquaculture or fish farming. Larger fish processing companies often operate their own fishing fleets or farming operations. The products of the fish industry are usually sold to grocery chains or to intermediaries. Fish are highly perishable. A central concern of fish processing is to prevent fish from deteriorating, and this remains an underlying concern during other processing operations. Fish processing can be subdivided into fish handling, which is the preliminary processing of raw fish, and the manufacture of fish products. Another natural subdivision is into primary processing involved in the filleting and freezing of fresh fish for onward distribution to fresh fish retail and catering outlets, and the secondary processing that produces chilled, frozen and canned products for the retail and catering trades. There is evidence humans have been processing fish since the early Holocene. These days, fish processing is undertaken by artisan fishermen, on board fishing or fish processing vessels, and at fish processing plants.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.